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Dendritic cells (DCs) initiate and control immune responses, participate in the maintenance
of immunological tolerance and are pivotal players in the pathogenesis of autoimmunity.
In patients with autoimmune disease and in experimental animal models of autoimmunity,
DCs show abnormalities in both numbers and activation state, expressing immunogenic
levels of costimulatory molecules and pro-inflammatory cytokines. Exogenous and endoge-
nous danger signals activate DCs to stimulate the immune response. Classic endogenous
danger signals are released, activated, or secreted by host cells and tissues experiencing
stress, damage, and non-physiologic cell death; and are therefore referred to as damage-
associated molecular patterns (DAMPs). Some DAMPs are released from cells, where
they are normally sequestered, during necrosis (e.g., heat shock proteins, uric acid, ATP,
HMGB1, mitochondria-derived molecules). Others are actively secreted, like Type I Inter-
ferons. Here we discuss important DAMPs in the context of autoimmunity. For some,
there is a clear pathogenic link (e.g., nucleic acids and lupus). For others, there is less
evidence. Additionally, we explore emerging danger signals.These include inorganic mate-
rials and man-made technologies (e.g., nanomaterials) developed as novel therapeutic
approaches. Some nanomaterials can activate DCs and may trigger unintended inflamma-
tory responses. Finally, we will review “homeostatic danger signals,” danger signals that
do not derive directly from pathogens or dying cells but are associated with perturbations
of tissue/cell homeostasis and may signal pathological stress. These signals, like acidosis,
hypoxia, and changes in osmolarity, also play a role in inflammation and autoimmunity.
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INTRODUCTION
Dendritic cells (DCs) are specialized antigen-presenting cells
(APCs) that help maintain peripheral tolerance and orchestrate
the adaptive immune response by presenting both endogenous
and exogenous antigens and producing immune modulatory fac-
tors, such as costimulatory/inhibitory molecules and cytokines
(Banchereau et al., 2000; Hammer and Ma, 2013). DCs reside in
virtually all the tissues of our body in a predominantly antigen-
capturing state and maintain immunologic tolerance by rou-
tinely migrating to the draining lymph nodes and presenting
self-antigens to lymphocytes in a tolerogenic manner (Steinman
et al., 2003; Reis e Sousa, 2006). Upon stimulation, DCs undergo
a process of maturation/activation, which allows them to present
in an immunogenic fashion the antigens captured in the periph-
ery and initiate immune responses (Cella et al., 1997; Blander and
Medzhitov, 2004). Danger signals are molecules released during
infections (Janeway, 1989; Medzhitov and Janeway, 1997b) and/or
tissue damage and cellular stress (Matzinger, 1994, 1998, 2002;
Gallucci and Matzinger, 2001; Land and Messmer, 2012). Danger
signals activate DCs and stimulate both the innate and adaptive
immune response (Box 1).
The recognition of tissue and cell damage – which may
involve several types of innate immune cells beside DCs and
cascades such as the complement – has been proposed to initi-
ate multiple processes (Bianchi, 2007), including: (a) the devel-
opment of inflammation, (b) the induction of innate effector
functions leading to pathogen clearance, (c) the stimulation
of adaptive immunity, which generates immunological mem-
ory for future encounters with the same antigen, and (d) the
stimulation of tissue repair processes, necessary to reconsti-
tute tissue integrity compromised by the infection or, in some
cases, by the immune response itself (Stoecklein et al., 2012)
(Figure 1).
Dendritic cells collaborate with other cells of the innate
immune system to initiate what is often called “sterile inflam-
mation and immunity;” that is, the activation of the innate and
adaptive immune response in the absence of pathogens (Rock
and Kono, 2008). Mechanisms of sterile inflammation are key to
our understanding of clinical situations such as transplant rejec-
tion, tumor immunity, chronic inflammatory diseases, trauma-
induced systemic inflammatory response syndrome (SIRS), and
other inflammatory conditions like ischemia-reperfusion injury
and atherosclerosis – in which immune responses develop when
no overt infection is present. Autoimmune diseases, in which the
adaptive immune system mounts an immune response against
self-antigens, are also an important class of pathologies in which
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Box 1 Terms and definitions.
In order to help our readers, here we define the terms we use throughout this review:
Pathogen-associated molecular pattern: molecular structures common to bacteria, viruses, or other microorganism, like LPS, flagellin,
and peptidoglycan, that are able to activate DCs. These molecules are recognized by pattern recognition receptors (PRRs) expressed on
both immune and non-immune cells. Since PAMPs are also expressed by the normal flora of mammalian mucosas, they are also called
Microbial Associate Molecular Patterns (MAMPs).
Damage-associated molecular pattern: endogenous molecular structures that are normally contained within the cell interior and hid-
den from the immune system, and are liberated upon tissue damage. Examples include ATP, HSPs, and HMGB1. These molecules are
recognized by a number of receptors, including PRRs, and are capable of inducing inflammation and immune responses in the absence of
infection.
Danger signal: a danger signal may be any substance or event that is able to activate DCs and therefore initiate immune responses. For
the purposes of this review, we have split the danger signals into three categories shown below. They all have in common an association
with cellular stress and the ability to activate DCs.
Classic danger signals: we use the term “classic” to refer to danger signals that are not emerging or homeostatic (defined below).
The classic danger signals are molecular species either associated with pathogens (PAMPs) or directly derived from tissue injury
damage-associated molecular patterns (DAMPs) as described above, or secreted by activated immune cells as amplifiers of the immune
activation.
Emerging danger signals: we use the term “emerging” to turn attention to new fields of research and technology that may pose new
challenges to the immune system. Specifically, emerging danger signals include inorganic materials and man-made technologies (e.g.,
nanomaterials) often used as novel therapeutic strategies. These materials have the potential to activate DCs directly or indirectly by
inducing tissue damage and release of DAMPs.
Homeostatic danger signals: with the term “homeostatic” we aim to highlight a less appreciated category of endogenous danger
signals. Homeostatic danger signals generally represent perturbations in tissue steady state often as a result of inflammation. These
perturbations include (but are not limited to) hypoxia, changes in acidity, or osmolarity, and metabolic stress.
the role of infectious triggers for immunity is still controver-
sial (Mills, 2011; Stranger and De Jager, 2012). The aim of this
review is to analyze the danger signals that modulate DC func-
tions and explore how those danger signals may contribute to the
pathogenesis of autoimmunity.
DENDRITIC CELLS IN AUTOIMMUNITY
The DC lineage comprises a complex population of several sub-
sets – with recent advances demonstrating intricacies of gene
transcription (Miller et al., 2012) and tissue localization (Gerner
et al., 2012) that define each population. Indeed, DC subsets vary
greatly in terms of lineage markers, cytokine production, and abil-
ity to stimulate different immune responses, largely depending on
the tissue in which they reside or emigrate from [i.e., skin (Gin-
houx et al., 2012) or gut (Rescigno, 2010)]. For simplicity, DCs are
categorized as conventional DCs, strong APCs, or plasmacytoid
DCs, the major producers of Type I Interferons (IFNs). DCs are
either resident within the secondary lymphoid organs like lymph
nodes and spleen, or migratory, coming into the lymph nodes from
the peripheral tissues (Hammer and Ma, 2013).
The importance of DCs in the pathogenesis of autoimmune
diseases is supported by the effects of their manipulation in exper-
imental animal models. Indeed, the constitutive genetic depletion
of DCs induces spontaneous development of autoimmunity char-
acterized by autoantibodies against nuclear and tissue-specific
antigens, multi-organ lymphocyte infiltration, and severe tissue
damage, especially in the intestine (Ohnmacht et al., 2009). There-
fore, DCs may be necessary for the establishment and main-
tenance of immunological self-tolerance (Reis e Sousa, 2006).
Paradoxically, DCs also seem to be powerful inducers of autoim-
munity. Mice in which DCs accumulate as a result of a DC specific
defect in apoptosis also develop chronic lymphocyte activation
and lupus-like systemic autoimmunity (Chen et al., 2006). Con-
sequently, uncontrolled DC functions are sufficient to prime for
autoimmune reactions. In many experimental models of autoim-
munity, DCs accumulate in the secondary lymphoid organs and
in the tissues targeted by the autoimmune process (Rosmalen
et al., 2000; Kalled et al., 2001; Adachi et al., 2002; Colonna et al.,
2006), although the causative mechanism for this accumulation
remains unclear. Further support comes from studies demon-
strating that the uptake of autoantibody-opsonized apoptotic cells
increases DC presentation of self Ags in an inflammatory context
(Frisoni et al., 2005). Moreover, in vivo priming with immunogenic
(highly activated), self-antigen-loaded DCs induces, or accelerates
autoimmunity (Bondanza et al., 2003; Eriksson et al., 2003), while
the administration of tolerogenic DCs reduces disease and has
been proposed as a potential therapeutic strategy in many models
of autoimmune disease, such as type I diabetes (Feili-Hariri et al.,
2002) and experimental autoimmune encephalomyelitis (EAE)
(Menges et al., 2002; Toscano et al., 2010).
Dendritic cells may play a pathogenic role in autoimmunity by
presenting self-antigens to T cells in an immunogenic fashion and
by collaborating in the activation of autoreactive B cells. To do
so, DCs have to be activated and express immunogenic costimu-
latory molecules and pro-inflammatory cytokines. Indeed, much
evidence shows abnormally activated DC phenotypes in patients
with different autoimmune diseases, as well as in murine mod-
els of autoimmunity (reviewed in Amodio and Gregori, 2012). In
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FIGURE 1 |The dendritic cell response to danger. (A) Exogenous
danger signals include pathogen-associated molecular patterns, as well as
exogenous particulate matter. Exogenous danger signals activate DCs
directly via pattern recognition receptors, or indirectly though tissue
damage (B) and homeostatic perturbations (C). (B) Inflammatory cell
death as a result of tissue injury or programed necrosis causes the release
of endogenous danger signals (D) (seeTable 1) which also activate DCs
(seeTable 1). (C) Homeostatic perturbations such as those found in
inflamed tissue (e.g., decreased pH, hypoxia) may also act as endogenous
danger signals, influencing DC immune functions. (E) DCs integrate both
exogenous and endogenous danger signals in order to orchestrate the
appropriate immune response.
some autoimmune strains of mice, DCs show abnormalities even
when generated in culture, far removed from the autoimmune
microenvironment (i.e., DCs from young mice, before the onset
of the disease) (Sriram et al., 2012). These results suggest a genetic
defect intrinsic to DCs, leading to their excessive activation, possi-
bly through an uncontrolled production of danger signals (Elkon
and Stone, 2011). In other cases, abnormalities were present only in
DCs in vivo or isolated ex vivo from diseased mice, therefore point-
ing to a direct association with the autoimmune process (Colonna
et al., 2006; Melli et al., 2009) and suggesting that in some situa-
tions DC abnormalities are a consequence rather than the cause
of the autoimmune environment. In either case, determining the
role of danger signals in the activation of DCs is key to better
understanding the pathogenesis of autoimmune disease. Knowl-
edge of danger signals will also facilitate the identification of novel
therapeutic approaches aimed at the prevention of autoreactive
lymphocyte activation. For example, neutralization of stimuli that
induce abnormal DC activation may be a far more physiologic
strategy than relying on general suppression of the lymphocyte
response, as is common with most current therapeutic protocols.
THE EXTENDED FAMILY OF DANGER SIGNALS
The term “danger signal” was originally proposed by Polly
Matzinger to indicate endogenous molecules released by stressed
or necrotic cells, which are able to activate DCs (Matzinger,
1994, 1998; Gallucci et al., 1999; Gallucci and Matzinger,
2001). Five years earlier, Janeway (1989) had theorized that the
innate immune system becomes activated by conserved molecu-
lar species expressed by evolutionarily distant microorganisms.
These features were called pathogen-associated molecular pat-
terns (PAMPs) and were proposed to trigger PRRs present on
host cells (Medzhitov and Janeway, 1997a,b). With his innov-
ative theory, Janeway (1992) updated the classic self-non-self-
discrimination model of immunity by theorizing that the immune
system can distinguish between self and infectious non-self, i.e.,
the pathogen (Medzhitov et al., 1997; Poltorak et al., 1998).
As our understanding of the biochemical basis of the PRRs
(e.g., TLRs, NLRs, RIG-I) has improved, it has become clear
that host factors, derived from damaged tissues and cells, sig-
nal through the same receptors, serving as “danger signals” to
stimulate immunity and therefore allow the immune system to
discriminate what is dangerous or damaged from what is not,
as previously theorized by Matzinger (1994, 2002) (Figure 1).
These endogenous danger signals are a subset of what Seong and
Matzinger (2004) named “DAMPs,” analogous to the nomencla-
ture of Janeway. Presently the term “danger signal” has a broad
meaning and includes very different families of molecules that
activate DCs: either exogenous molecules, such as the PAMPs;
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or endogenous molecules released, activated, or secreted by host
cells and tissues undergoing stress, damage, and non-physiological
cell death, namely DAMPs (Matzinger, 1998, 2002) (Figure 1;
Table 1). We support this inclusive nomenclature as it conveys
the idea that both pathogens and trauma/stress are inducers
of tissue and cell damage, which results in a pathologic sta-
tus that is required for the activation of the innate immune
system.
In the next section, we will review the DAMPs that activate
DCs in autoimmunity, and we will then focus on danger sig-
nals that are less in the spotlight for immunologists, although
already hypothesized in the original version of the Danger Model
Table 1 | Endogenous danger signals.
Signal Source Receptor/sensor(s)
Nucleic Acids Dead/dying cells TLR-7, -8, -9








A1, A2A, A2B, A3
Mitochondria
Activated platelets
Uric Acid Nucleic acid breakdown TLRs
Dead/dying cells CD14
Inflammasome
HSPs Cell interior TLRs
Dead/dying cells CD91
Mitochondria
HMGB1 Cell Nucleus TLRs
Necrotic cells RAGE
























Secreted by tumor cells Acid-sensing
G-proteins
Osmolarity Perturbation in homeostasis mTOR
Hypoxia Perturbation in homeostasis Mitochondria
(Matzinger, 1994): the emerging and the homeostatic danger
signals. Emerging danger signals are molecules that are newly
developed by modern technology and that can activate DCs either
by inducing cellular stress/damage or by attracting and carrying
endogenous danger signals. Finally, we will review “homeosta-
tic danger signals,” danger signals that do not derive directly
from pathogens or dying cells but rather are associated with
perturbations of tissue/cell homeostasis and may be considered
signs of stress and non-physiological conditions. We will not
review PAMPs since they have been subjects of many excellent
reviews.
ENDOGENOUS DANGER SIGNALS
Classic endogenous danger signals are molecules that activate DCs
(Table 1; Figure 1; Box 2). As DCs are central to antigen presenta-
tion and the initiation of the immune response, it was first shown
that DCs respond to endogenous danger signals released from
dying cells (Gallucci et al., 1999; Sauter et al., 2000), explaining
the adjuvant effects of dying cells when co-injected with antigen
in vivo (Gallucci et al., 1999; Shi et al., 2000, 2003).
Endogenous danger signals can be classified as “primary” when
secreted by stressed cells or released by dying cells, or as “sec-
ondary” when produced by activated immune cells (Gallucci and
Matzinger, 2001) (Box 2). Some cytokines act as both primary
and secondary danger signals, when they are secreted by dam-
aged/dying cells (Box 2). Many primary endogenous danger sig-
nals are released from the interior of the cell when the cell loses
plasma membrane integrity upon necrosis (Rock and Kono, 2008;
Sims et al., 2010). In contrast, the process of apoptosis keeps these
pro-inflammatory signals contained and can actively up-regulate
anti-inflammatory mediators (Behrens et al., 2007).
We will next describe some of the most studied DAMPs in
autoimmunity. Covering all possible endogenous danger signals
is not the purpose of this review: we will discuss a few signals in
detail with specific reference to their role in autoimmune diseases
(Table 1).
NUCLEIC ACIDS
Nucleic acids play a complex role in the pathogenesis of the
autoimmune disease systemic lupus erythematosus (SLE). Nucleic
acids are both the primary self-antigens and potent DAMPs, acti-
vating DCs through TLR7 and TLR9 and inducing the production
of Type I IFNs (Barrat et al., 2005; Marshak-Rothstein and Rifkin,
2007). Nucleic acids often activate DCs either as part of an immune
complex with autoantibodies (Leadbetter et al., 2002) or in com-
plex with chaperones like heat shock proteins (HSP) and HMGB1.
Oligonucleotides that inhibit the response to TLR7 and TLR9 ame-
liorate disease in lupus-prone mice (Barrat et al., 2007). Similarly
the genetic deficiency of TLR7, or TLR7 and TLR9 combined pre-
vent disease, while the single deficiency of TLR9 renders the disease
worse, suggesting a double-edge effect of TLR9 (Santiago-Raber
et al., 2009). In our hands, DCs from lupus-prone mice express
constitutively high levels of Type I IFNs and IFN responsive genes
and this IFN Signature was diminished by treatment with oligonu-
cleotides inhibitory for TLR7 and TLR9, supporting a role for the
response of DCs to nucleic acids in the excessive production of
Type I IFNs in lupus (Sriram et al., 2012). The importance of TLR7
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Box 2 Primary vs. secondary endogenous danger signals.
Endogenous danger signals can be divided in two categories depending on the trigger and on the cellular source.
Primary endogenous danger signals: endogenous molecules that are normally contained within the cell interior or present in an inactive
form, hidden from the immune system, and mostly performing non-immune functions.They are released upon tissue damage and are able
to activate DCs by triggering a number of receptors, including PRRs. They are the first initiators of sterile immunity. Examples are listed in
Table 1.
Secondary endogenous danger signals: endogenous molecules that are actively secreted by immune cells upon activation to mediate
innate and adaptive immune activation in an autocrine and paracrine manner. They fuel and direct both sterile and non-sterile immunity.
Secondary endogenous danger signals include lymphocyte-derived activators of DCs such as CD40-L (Ridge et al., 1998) and granulysin
(Zitvogel and Kroemer, 2010); neutrophil-derived alarmins (Yang et al., 2009) and pro-inflammatory cytokines such asTNF-α, Type I IFNs, and
HMGB1.
is further highlighted by the discovery that the Yaa translocation of
a piece of chromosome X, containing 16 genes including TLR7, to
the Y chromosome induces in male mice a severe lupus-like disease
by creating a duplication of TLR7 (Pisitkun et al., 2006). Necrotic
cells are a source of immunogenic nucleic acids (Eloranta et al.,
2009) as well as neutrophils undergoing NETosis (Garcia-Romo
et al., 2011).
ENDOGENOUS VIRAL ELEMENTS
A subset of PAMPs that can also be considered a form of spe-
cial endogenous danger signals are endogenous viral elements
(EVEs). EVEs are sections of viral DNA that have integrated into
the mammalian genome during evolution (Stoye, 2012). The best
characterized EVEs come from retroviruses, but may also derive
from other viruses (Katzourakis and Gifford, 2010). Recent evi-
dence demonstrates that defects in controlling retroviral elements
are linked to autoimmunity. Indeed, mice deficient in the cyto-
plasmic three prime repair exonuclease 1 (Trex1) (formerly DNase
III) express elevated IFN alpha (IFNα) levels in many organs and
develop inflammatory myocarditis in the absence of viral infection
(Morita et al., 2004). Trex1-deficient (Trex1−/−) murine embry-
onic fibroblasts accumulate endogenous retroviral DNA in the
cytosol which induces excessive Type I IFN production via STING
(Yang et al., 2007; Stetson et al., 2008; Gall et al., 2012). Loss-of-
function mutations in Trex1 are present in patients with Aicardi–
Goutières syndrome as well as other autoimmune diseases such
as familial chilblain lupus (Lee-Kirsch et al., 2007a; Gunther et al.,
2009) and SLE (Lee-Kirsch et al., 2007b; Hur et al., 2008). This evi-
dence suggests that cytoplasmic DNA derived from endogenous
retroviruses is an endogenous danger signal that, if not scavenged
by Trex1, can trigger an intracellular nucleic acid-sensing machin-
ery (Pichlmair and Reis e Sousa, 2007; Thompson et al., 2011),
leading to excessive production of the pro-autoimmunogenic Type
I IFNs (Elkon and Stone, 2011). Although DCs are activated by
Type I IFNs (Gallucci et al., 1999), and might therefore become
hyperactivated, and thus initiate the autoimmune process, phe-
notypic, or specific functional abnormalities of DCs in Trex1−/−
mice or in patients with Aicardi–Goutières syndrome have not yet
been reported.
ATP
Other forms of nucleic acids acting as danger signals are the
intracellular single nucleotides ATP and UTP. Extracellular ATP
concentration is typically kept very low (10 nM) by ectonucleoti-
dases (Robson et al., 2006). Under pathologic conditions, however,
local concentrations of ATP can be increased – when liberated
from damaged tissue or when released by an active process such as
platelet or phagocyte activation (Zeiser et al., 2011). These adeno-
sine derivatives activate DCs (Marriott et al., 1999) by stimulating
the high affinity purinergic receptors P2Z/P2X7 (Mutini et al.,
1999). ATP and UTP activate the inflammasome in collaboration
with TLRs (Mariathasan et al., 2004) and mediate at least some
of the sterile inflammation induced by necrotic cells (Iyer et al.,
2009; Aymeric et al., 2012). P2X7-activated DCs have been shown
to be crucial for the induction of tumor immunity (Ghiringhelli
et al., 2009), the lack of P2X7 signaling decreases the severity of
EAE (Sharp et al., 2008), and oxidized ATP (oxATP), an inhibitor
of the ATP receptor P2rx7, ameliorated autoimmune type I dia-
betes and autoimmune encephalitis in mice (Lang et al., 2010).
Apoptotic cells can also release small amounts of ATP through the
pannexin family of plasma membrane channels. At this low con-
centration, ATP binds low affinity purinergic receptors, including
P2Y2 and P2X7 on phagocytes and recruits them to accelerate non-
inflammatory clearance of apoptotic cells (Elliott et al., 2009).
In a model of allergic lung inflammation, P2Y2 is required for
myeloid DC and eosinophil migration, although this receptor does
not seem to be involved in DC maturation (Muller et al., 2010).
Therefore, the ATP molecule may represent an important DAMP,
conserved from prokaryotes (Atarashi et al., 2008) to plants (Heil
et al., 2012) to mammals (Aymeric et al., 2012), acting as an activa-
tion signal at high doses when released by damaged cells, while at
lower doses it may act as a “find-me” signal that helps housekeep-
ing clearance of apoptotic cells and prevents immune activation
(Elliott et al., 2009).
URIC ACID
Uric acid was one of the first DAMPs to be discovered and is partly
responsible for the adjuvant properties of dying cells (Shi et al.,
2003). Uric acid is a product of purine metabolism and is nor-
mally soluble inside cells. When released in the extracellular space
uric acid precipitates and forms insoluble crystals of monosodium
urate (MSU) capable of activating DCs in vitro and of acting as
an adjuvant in vivo (Shi et al., 2003; Rock et al., 2010). Extra-
cellular uric acid is highly inflammatory when it accumulates in
joints to cause gout (Rock et al., 2013) or when it is released in large
amounts during anti-cancer therapy causing tumor lysis syndrome
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(Muslimani et al., 2011). The inflammatory nature of uric acid, as
well as of other crystals like silica and alum, is in part due to their
ability to activate the inflammasome (Martinon et al., 2006) with
the extracellular delivery of endogenous ATP, the stimulation of
IL-1β, and other pro-inflammatory cytokines, and the induction
of reactive oxygen species (ROS) (Schorn et al., 2010; Riteau et al.,
2012). These crystals may activate the inflammasome by caus-
ing direct cell damage to phagocytes, including DCs, inducing
phagolysosome rupture (Hornung et al., 2008). Indeed, mem-
brane fragments of these organelles can activate several responses,
including polyubiquitination, autophagy, and pyroptosis and may
play a role in host defense against intracellular parasites (Hilbi,
2009). Excessive activation of the inflammasome has been strongly
linked to a group of hereditary autoinflammatory diseases called
cryopyrin associated periodic syndromes (Lamkanfi and Dixit,
2012) but it may also play a role in more classic autoimmune
diseases such as multiple sclerosis (MS) as mice deficient for com-
ponents of the inflammasome (Nlrp3 and ASC) are protected from
the development of EAE (Gris et al., 2010; Shaw et al., 2010).
HEAT SHOCK PROTEINS
Heat shock proteins are the most abundant proteins in cells,
responsible for maintaining the correct folding of nascent and
misfolded proteins, and of proteins that must remain inactive for
long periods. HSPs are up-regulated in response to tissue stressors
such as elevated temperature, osmotic shock, and cytotoxic agents
(Srivastava, 2002). During cellular necrosis, HSPs are released into
the extracellular space where they activate the innate immune
response by triggering TLRs (Vabulas et al., 2002). As HSPs are
protein chaperones, they also actively participate in DC antigen
processing and presentation to initiate adaptive immunity (Srivas-
tava, 2002). Srivastava’s group showed that necrotic cells, but not
apoptotic cells, release many HSPs such as HSP70, HSP90, calreti-
culin, and GP96 (Basu et al., 2000), which may activate immunity
through the common receptor CD91 (Binder et al., 2000). In con-
trast, other HSPs, like the human heat shock protein 60, induce DC
maturation and promote a Th1 phenotype via TLR4 (Flohe’ et al.,
2003). Like HMGB1 and autoantibodies, HSPs may contribute to
the development of autoimmunity not only as endogenous adju-
vants but also as chaperones that physically deliver autoantigens
to APCs (Biswas et al., 2006). This is the mechanism by which
HSP70 promotes autoimmunity in a mouse model of diabetes
(Liu et al., 2003; Millar et al., 2003). Furthermore, autoantibod-
ies against HSPs are found in SLE patients and allelic variants of
the Hsp70 genes are significantly associated with SLE (Furnrohr
et al., 2010) and with several other autoimmune diseases such
as MS (Ramachandran and Bell, 1995), Crohn’s disease (Debler
et al., 2003), Grave’s disease (Ratanachaiyavong et al., 1991), and
insulin-dependent diabetes mellitus (Pociot et al., 1993).
HIGH MOBILITY GROUP BOX PROTEIN 1
High mobility group box protein 1 (HMGB1) is a well-established
endogenous danger signal (Lotze and Tracey, 2005), released by
necrotic cells that have lost membrane integrity (Scaffidi et al.,
2002) as well as secreted by phagocytic cells as a late mediator
of inflammation (Gardella et al., 2002). HMGB1 normally has a
nuclear localization and was originally described as a DNA binding
protein (Javaherian et al., 1978; Bianchi et al., 1989), but a variety
of other cellular functions have been attributed to HMGB1 largely
depending on different post-translational modifications such as
oxidation and hyperacetylation (Harris et al., 2012). Intracellular
HMGB1 regulates gene transcription and autophagy (Tang et al.,
2012). Extracellular HMGB1 acts as a classic DAMP when released
by necrotic cells, or as a secondary danger signal when secreted
by macrophages and DCs in response to LPS and TNF-α (Yang
et al., 2005; Bianchi, 2007). Autocrine HMGB1 mediates DC acti-
vation and the ability to induce Th1 polarization (Dumitriu et al.,
2005). The secretion of HMGB1 by monocytic cells is mediated by
hyperacetylation of HMGB1, which localizes it to the cytoplasm
where, upon a secondary signal, it is liberated into the extracellular
compartment (Bonaldi et al., 2003).
HMGB1 is significantly increased in the serum of patients with
brain and myocardial ischemia (Goldstein et al., 2006) and in septic
patients in which it mediates the late phase of septic shock (Wang
et al., 1999). HMGB1 is recognized by many receptors, like the
receptor for advanced glycation end products (RAGE) (Kokkola
et al., 2005) as well as by TLR2 and TLR4 (Park et al., 2004),
CD24-Siglec10, and the recently reported TIM-3 (Chiba et al.,
2012). When bound to the chemokine CXCL12, HMGB1 acts as
a chemokine to recruit leukocytes to the site of inflammation by
binding CXCR4 (Schiraldi et al., 2012). The shift from function-
ing as a chemokine to acting as a danger signal depends on its
redox state: intracellular HMGB1 has three cysteines that are in a
reduced state (all-thiol state); when it is secreted or released, the all-
thiol HMGB1 can bind to CXCL12 and chemoattract unless two
cysteines are oxidized, forming a disulfide bond and promoting
HMGB1 danger signal functions (Yang et al., 2013). During apop-
tosis HMGB1 is kept intracellular, and uptake of apoptotic cells
induces release of oxidized HMGB1 so that its pro-inflammatory
activities are neutralized. Possible functions of this fully oxidized
state are still under investigation (Yang et al., 2013).
Evidence suggests that HMGB1 participates in the pathogene-
sis of many autoimmune diseases like Rheumatoid Arthritis (RA),
SLE, EAE, and diabetes (Zhang et al., 2009; Harris et al., 2012).
For example, RA patients have increased levels of HMGB1 in the
serum and synovial fluid that decreases upon therapy-induced
amelioration of joint inflammation (Zetterstrom et al., 2008). Sim-
ilarly, HMGB1 blockade ameliorates arthritis in animals, while its
administration in the joints induces arthritis (Kokkola et al., 2003).
In SLE patients, serum HMGB1 levels, as well as anti-HMGB1
autoantibody titers, positively correlate with disease activity (Jiang
and Pisetsky, 2008; Abdulahad et al., 2011). HMGB1-containing
nucleosomes from apoptotic cells have been shown to induce
secretion of pro-inflammatory cytokines and expression of cos-
timulatory molecules in macrophages and DCs and the adminis-
tration of HMGB1-nucleosome complexes in mice induces lupus-
like autoantibodies (Urbonaviciute et al., 2008; Urbonaviciute and
Voll, 2011). In MS patients, extracellular HMGB1 is increased in
the cerebrospinal fluid (CSF) and microglia and macrophages
expressing cytosolic HMGB1 are increased in MS active lesions
(Andersson et al., 2008). In mice, HMGB1 drives neuroinflamma-
tion in EAE and the inhibition of HMGB1 signaling with a neutral-
izing antibody ameliorates disease (Robinson et al., 2013). Clinical
and experimental evidence also suggest a role for HMGB1 in the
Frontiers in Immunology | Antigen Presenting Cell Biology June 2013 | Volume 4 | Article 138 | 6
Gallo and Gallucci Dendritic cells, danger signals, and autoimmunity
pathogenesis of type I diabetes. In diabetes-prone NOD mice,
HMGB1 blockade significantly inhibited insulitis progression and
delayed diabetes onset, decreased the number, and maturation of
DCs in the pancreatic lymph nodes, and increased the number of
regulatory T cells (Han et al., 2008). Once diabetes has developed,
hyperglycemia can induce HMGB1 secretion (Yao and Brownlee,
2010; Dandona et al., 2013) and HMGB1 may contribute to the
nephropathy and the vascular complications of diabetes by fuel-
ing inflammation and promoting tissue damage, especially in the
kidney (Lin et al., 2012). Higher levels of serum HMGB1 were
associated in type 1 diabetes patients with a higher risk of mortal-
ity, cardiovascular disease (Nin et al., 2012a), and kidney damage
(Nin et al., 2012b).
In summary, HMGB1 is a powerful danger signal that plays
a complex role in the pathogenesis of autoimmune diseases.
Blockade of HMGB1 has thus far proven to be beneficial in
ameliorating a number of types of experimental autoimmunity,
making its therapeutic potential very promising. Further inves-
tigation is still needed to dissect the role of HMGB1 as an acti-
vator of DCs in terms of its multiple functions as a cytokine,
chemokine, transcription regulator, and possible functions yet to
be discovered.
TYPE I INTERFERONS
Type I IFNs activate DCs in vitro and act as adjuvant in vivo
(Gallucci et al., 1999). They are secreted by virally infected cells
(Taniguchi and Takaoka, 2002) as a primary danger signal to alert
both neighboring tissue cells and local immune cells to the pres-
ence of a viral infection. They are also secreted by immune cells as
an amplifier of innate immunity (Liu, 2005). Type I IFNs (IFNs α
and β) mediate the activation of DCs to promote adaptive immune
responses such as cross-priming and isotype switching of respond-
ing murine B cells toward IgG2 (Theofilopoulos et al., 2005). Type
I IFNs are particularly important in autoimmunity and especially
in SLE in which an IFN Signature is present – an abnormally high
expression of Type I IFN responsive genes in immune cells and
tissues (Baechler et al., 2003; Bennett et al., 2003; Crow et al.,
2003; Elkon and Stone, 2011). The hyper-activation of Type I
IFNs may play a role in the early and most acute phases of dis-
ease because the IFN Signature is common in pediatric patients
(Bennett et al., 2003) and in adults with central nervous sys-
tem involvement and nephritis (Baechler et al., 2003). Supporting
this notion, we have recently discovered that myeloid DCs and
pDCs from lupus-prone Sle1,2,3 mice express an IFN Signature
before the onset of autoimmunity. Even when generated in cul-
ture from bone marrow precursors, depleted of mature T and B
cells, macrophages, and DCs, and thus, severed from the in vivo
pro-autoimmune environment, DCs from Sle123 mice expressed
an IFN Signature (Sriram et al., 2012). These results indicate that
DCs are an independent cellular source of the pathogenic dan-
ger signals implicated in lupus (Elkon and Stone, 2011; Sriram
et al., 2012). Since polymorphisms in genes that are part of the
signaling pathway of Type I IFNs, such as IRF5, IRF7, and STAT4,
are associated with a higher risk of developing SLE (Harley et al.,
2009), the over-expression of Type I IFNs in these patients may
be the result of the combination of genetic predisposition to pro-
duce high levels of Type I IFNs and exposure to danger signals
that stimulate IFN production (Elkon and Stone, 2011; Niewold,
2011).
DEGRADATION PRODUCTS OF THE EXTRACELLULAR MATRIX
During tissue damage, not only are cells stressed and dying but
components of the extracellular matrix (ECM) are disrupted
leading to the production of low molecular weight degradation
products such as hyaluronic acid (HA) and heparan sulfate, which
have been shown to activate DCs and initiate inflammation (Ter-
meer et al., 2002; Shirali and Goldstein, 2008; Brennan et al.,
2012). Moreover, other components of the ECM such as fibrino-
gen, fibronectin extra-domain A (EDA), biglycan, and tenascin-C
are up-regulated in response to tissue injury, and they all act as
danger signals involved in the pathogenesis of RA (Goh and Mid-
wood, 2011). Many of these molecules have been found increased
in RA tissues; administration of danger signals, such as fibronectin
EDA or tenascin-C, induces joint inflammation in vivo, while mice
deficient in tenascin-C show a rapid resolution of inflammation
(Goh and Midwood, 2011), indicating an important role for ECM
molecules as initiator/amplifiers of the autoimmune process in RA.
EMERGING EXOGENOUS DANGER SIGNALS
The classic exogenous danger signals originate from pathogens
(PAMPs), but exogenous particles not derived from microbes, such
as silica, crystals, and nanoparticles can also induce DC activation
and inflammatory disease. Indeed, it has long been known that
inhalation of fine particulate material can cause inflammatory
and fibrotic lung disease (i.e., pneumoconiosis). The inflamma-
tory nature of non-living particulate matter, like crystals and
nanoparticles, may stem in part from their hydrophobic char-
acter (Seong and Matzinger, 2004). Moreover, nanoparticles are
preferentially taken up by phagocytes (Dobrovolskaia et al., 2008),
including DCs, in which they cause destabilization and rupture
of the phagolysosome (Hornung et al., 2008), leading to inflam-
masome activation (Cassel et al., 2008). Therefore, extracellular
inorganic material may directly damage DCs, leading to inflam-
masome activation and DC maturation. This is the proposed
mechanism of action for alum, a widely used adjuvant in human
vaccines (Eisenbarth et al., 2008). Because of their immunogenic
potential, it is important to consider the emerging use of nano-
materials to target DCs for novel therapeutics and their possible
autoimmunogenic side effects.
NANOMATERIALS
The term nanoparticle may apply to almost any material with
individual units at the nano scale. Nanomaterials can be gener-
ated from organic (e.g., liposomes, organic polymers) or inorganic
materials (e.g., gold, silver) and engineered to display a molecule
of interest or contain a therapeutic payload. Using nanoparticles
and synthetic material systems, it may be possible to modu-
late the immune response through direct manipulation of DCs
(Elamanchili et al., 2007).
The usefulness of pro-inflammatory nanoparticles has been
demonstrated in a number of fields (Fadeel, 2012; Fadeel et al.,
2012). For example, nanoparticle-based co-delivery of antigens
and danger signals directly to DCs may be a promising strategy to
direct anti-tumor immune responses (Kim and Mooney, 2011), as
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well as useful in next-generation vaccine adjuvants (Demento et al.,
2009). However, because materials designed as next-generation
therapies are sometimes capable of inducing DC-mediated inflam-
mation similarly to PAMPs or DAMPs (Koike et al., 2008; Li et al.,
2010), nanomaterials may raise concerns for safety (Dobrovolskaia
and McNeil, 2007; Stern and McNeil, 2008). For example,nanopar-
ticle debris from prosthetic alloys can activate the inflammasome
(Caicedo et al., 2009), nanoparticles are known to modulate vari-
ous forms of inflammatory cell death (Andón and Fadeel, 2013),
and some nanomaterials are strong activators of complement
(Salvador-Morales et al., 2006).
Additionally, it is now clear that nanoparticles do not stay
“naked” when introduced in vivo – they become coated by bio-
molecules (e.g., proteins) to form what is termed a bio-corona
(Fadeel, 2012). The composition and biophysical properties of
the bio-corona is likely to have major implications for safety and
effectiveness of future therapies (Aggarwal et al., 2009). The pro-
tein bio-corona first develops as a “soft” coat which eventually
becomes a compact “hard” shell, becoming difficult to remove
(Mohamed et al., 2012). Proteins within the hard coat are therefore
aggregated and may become unfolded or modified (for example,
citrullinated), possibly resulting in DCs recognizing altered self-
antigen as danger signals, although evidence for this is still lacking
(Fadeel, 2012).
The study of nanoparticle characteristics is also likely to
uncover as yet unknown characteristics of danger signals. With
the ability to control the characteristics and the delivery of the
“danger signal,” we may better understand the immune response
to those factors. For example, size of the nanoparticle seems to
determine which DC populations interact with an injected parti-
cle: namely, larger particles require peripheral DCs for transport
into the draining lymph nodes, whereas smaller particles act on
lymph node resident cells directly (Manolova et al., 2008). Large
particles also tend to be more inflammatory, with smaller particles
often eliciting no reaction at all (Fadeel, 2012), possibly because
larger sized particles more potently destabilize the phagolysosome.
Although most studies focus on the pro-inflammatory nature
of particulate matter, some nanomaterials may suppress immune
function (Mitchell et al., 2009; Zolnik et al., 2010) or can be engi-
neered to evade the innate immune system (Moghimi, 2002).
Indeed, gold has anti-inflammatory properties that have been
exploited for many years in treatment for RA and gold nanopar-
ticles are being engineered as novel treatments for a number of
inflammatory diseases (Ulbrich and Lamprecht, 2010). Recently,
Yeste et al. used gold nanoparticles to generate tolerogenic DCs in
a murine model of EAE by delivering a tolerogenic compound in
combination with oligodendrocyte antigen to DCs. These DCs in
turn induced the generation of regulatory T cells which mitigated
disease progression (Yeste et al., 2012).
Although gold may have some anti-inflammatory properties
and may be useful as a delivery system, it also has many toxic side
effects, earning itself a black box warning and precluding it as a
practical therapy. Indeed,heavy metals can cause autoimmune-like
syndromes (Schiraldi and Monestier, 2009) and therefore should
be implemented cautiously as therapeutics. However, it is impor-
tant to note that nanoparticles are being developed which are both
biocompatible and biodegradable. For example, liposomes have
been used as a delivery system to successfully treat experimental
murine arthritis (Metselaar et al., 2003; Sethi et al., 2013), and
biodegradable nanoparticles have been used to localize and target
T cells (Fahmy et al., 2007). Nanoparticles coated with glycans have
been used to target antigen to DCs (García-Vallejo et al., 2013),
but the therapeutic use of DC-targeted nanoparticles in spon-
taneous autoimmunity remains largely unexplored (Ulbrich and
Lamprecht, 2010). Nanomaterials therefore represent a promising
strategy for next-generation therapy in the autoimmune diseases
and an important area for future investigation to insure their safety
and efficacy.
HOMEOSTATIC ENDOGENOUS DANGER SIGNALS
So far, we have briefly described the DAMPs investigated under
the classic paradigm – cell stress/death from tissue damage, pos-
sibly induced by trauma, infections or foreign materials, provides
endogenous danger signals,which propagate the immune response
(Figure 1). But a number of investigations suggest the existence
of endogenous danger signals that do not derive from damaged
or dying cells. Rather, they are signals that alert immune cells, and
possibly non-immune cells, about perturbations in the steady state
of the cellular microenvironment, and we refer to these as “home-
ostatic” danger signals (Figure 2). Indeed, the immune system is
closely tied to metabolic homeostasis (reviewed in Odegaard and
Chawla, 2013; Pearce and Pearce, 2013). These homeostatic danger
signals may include conditions often characteristic of chronically
inflamed tissues such as localized acidosis, changes in osmolarity,
decreased oxygen tension (hypoxia), oxidative stress with ROS, and
other metabolic disturbances – all possible causes of cellular stress
as hypothesized in the original Danger Model (Matzinger, 1994).
Homeostatic changes also result from bacterial growth and acute
tissue damage, further supporting the notion that cells may sense
homeostatic changes as danger. Some of these homeostatic pertur-
bations directly activate DCs, because DCs have specific sensors
for these perturbations, while others lead to expression of more
classic DAMPs: an example of the latter is the up-regulation of HSP
like HSP70 by DCs in response to hyperthermia (40 °C), resulting
in up-regulation of costimulatory molecules, pro-inflammatory
cytokines, and T cell stimulation (Knippertz et al., 2011).
ACIDITY
Physiologic pH is normally held within relatively narrow range
(pH 7.35–7.45). During localized inflammation (e.g., infection,
arthritic joint) or tissue ischemia (e.g., lupus nephritis, MS lesions)
extracellular pH can reach pH values as low as 5.5 (Treuhaft and
McCarty, 1971; Nedergaard et al., 1991; Simmen and Blaser, 1993).
A significant amount of research on cell functions in acidic
conditions comes from the cancer field. Tumor cells tend to use gly-
colysis for energy generation even when there is adequate oxygen
supply – the Warburg effect (Cardone et al., 2005). The ineffi-
ciency of glycolytic metabolism, the active secretion of acid, and
the poor perfusion in solid tumors is thought to contribute to an
acidic microenvironment. Acidic microenvironments increase the
invasiveness and metastatic potential of some cancers as a result of
remodeling of the ECM (Martinez-Zaguilan et al., 1996; Rofstad
et al., 2006) and activation of inflammatory processes that have
been shown to promote tumor survival (Grivennikov, 2013).
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FIGURE 2 | Examples of homeostatic danger signals. Localized
perturbations in homeostasis are common in infection, ischemia-reperfusion
injury, and inflammation associated with autoimmune disease. Extreme
temperatures can cause DC activation and cell death. Heat induces the
release of HSPs which can activate DC. Hypoxia is sensed by HIF and leads to
DC activation, NF-kB signaling, and cytokine production. Acidity is sensed by
acid-sensing ion channels and acid-sensing G-proteins, leading to DC
activation. Hypotonicity activates the inflammasome in macrophages and high
salt concentrations promote Th17 responses. How DCs respond to changes in
osmolarity remains unclear.
Several studies have indicated that acidity might act as a danger
signal. For example, extracellular acidification can promote acti-
vation of the inflammasome and secretion of IL-1β by monocytes
(Jancic et al., 2011) and seems to activate neutrophils through the
activation of PI3K-Akt and ERK pathways (Trevani et al., 1999;
Martinez et al., 2006). Additionally, non-immune cells may also
produce inflammatory cytokines in response to extracellular acid-
ification (Shime et al., 2008; Ichimonji et al., 2010) or may alter
cell death programs (Jouan-Lanhouet et al., 2012).
Acidity in the extracellular microenvironment was initially pro-
posed to inhibit DC differentiation (Gottfried et al., 2006), but
some work suggests that DCs are instead activated by acidosis
(Martinez et al., 2006). Other evidence has shown that acidic envi-
ronments might improve antigen uptake and antigen presentation
in DCs, although the mechanisms are still unclear (Vermeulen
et al., 2004). Recently, acid-induced activation of DCs was found to
be in part due to acid-sensing ion channels (Tong et al., 2011), but
our understanding of DC responses to protons remains limited
(Lardner, 2001). Low pH may also be sensed by proton-sensing
G protein-coupled receptors (Seuwen et al., 2006), as seen in
responses from synovial cells (Christensen et al., 2005; Tomura
et al., 2005). Acidity is a common feature of inflammation found
in many autoimmune diseases (e.g. within the arthritic joint,
nephritic kidney, ischemic lesions of MS). However, to our knowl-
edge, it is still unclear whether pathways triggered by acidity are
involved in DC immune functions in the context of autoimmune
diseases.
OSMOLARITY AND SALT
Cell volume expansion, as a result of extracellular hypotonicity,
may also act as a danger signal. In response to hypotonic osmotic
challenge lymphocytes first swell, then undergo a process termed
regulatory volume decrease (RVD) (Garber and Cahalan, 1997;
Cahalan et al., 2001). A reciprocal process occurs in hypertonic
environments called regulatory volume increase (RVI). RVD is
largely the result of the activity of potassium and chloride chan-
nels, with efflux of KCl giving way to water efflux as a result of
decreased intracellular osmolarity. In some cases KCl efflux also
leads to activation of other ion channels and cellular depolar-
ization, thus having major implications in fundamental cellular
processes like metabolism and cell death. Indeed, a similar process
is seen during apoptosis. Apoptotic cell volume decrease seems to
be due to the activation of the same potassium and chloride chan-
nels (Maeno et al., 2000, 2006). Cellular responses resulting from
homeostatic signals are complicated by the observation that ion
channels form complexes with integrins and may signal together
(Arcangeli and Becchetti, 2006).
Earlier studies demonstrated that hypotonicity influence
immune cell function, for example in neutrophil shedding of L-
selectin (Kaba and Knauf, 2001). Mammalian target of rapamycin
(mTOR), in conjunction with mitochondrial metabolism, may
also be an important sensor for osmotic stress, as well as other
homeostatic signals (Desai et al., 2002; Kwak et al., 2012). DCs
are able to pinocytose, uptake fluids from the extracellular com-
partment as a way to sample for antigens and danger signals. This
www.frontiersin.org June 2013 | Volume 4 | Article 138 | 9
Gallo and Gallucci Dendritic cells, danger signals, and autoimmunity
process is very efficient in immature/resting DCs which can uptake
fluids up to one thousand fold their volume (Sallusto et al., 1995).
This large flow of fluids requires a tight control of the DC volume,
and therefore DCs express aquaporins for this purpose (de Baey
and Lanzavecchia, 2000). Inhibition of aquaporins leads to sud-
den increase in cell volume, which may ultimately result in DC cell
death. The idea that hypotonicity may be regarded as a danger sig-
nal has recently gained credence with the finding that hypotonic
solutions activate the NLRP3 inflammasome in macrophages via
the efflux of K+ and Cl− ions and RVD (Compan et al., 2012). The
role of alterations of cell volume in DC physiopathology remains
largely unclear.
In contrast to hypotonicity, high salt concentrations do not
seem to activate inflammasome activation, as hypertonic solutions
are not able to induce caspase-1-dependent release of cytokines
IL-18 and IL-1β (Compan et al., 2012). However, high salt con-
centrations may promote development of other pro-inflammatory
conditions such as those associated with T helper 17 cells (Th17).
Osmotic shock due to high salt was known to induce the pro-
duction of IL-8 from human peripheral blood mononuclear cells
(Shapiro and Dinarello, 1995), but recently two groups have
demonstrated that high salt concentrations may promote patho-
genic Th17 responses (Kleinewietfeld et al., 2013; Wu et al., 2013)
and a high salt diet exacerbates EAE (Wu et al., 2013). These studies
suggest that elevated salt concentrations, similar to levels found in
tissues of animals on high salt diets, may exacerbate autoimmune
reactions. It is still unclear how high salt concentrations affect DCs
in vivo in the context of autoimmunity.
HYPOXIA
Decreased oxygen tension is another characteristic disturbance of
inflamed or damaged tissue (Nizet and Johnson, 2009). Innate
immune cells are thought to be better than adaptive immune cells
at surviving in such low oxygen conditions (Sica et al., 2011),
and a number of signaling pathways are relatively well known
(Gloire et al., 2006; Semenza, 2009). In normoxic conditions, the α
subunits of hypoxia-inducible factor (HIF), HIF-1α, and HIF-2α,
are constantly produced and promptly degraded. Under hypoxic
conditions, HIF-α accumulates, forms a dimer with the constitu-
tively expressed HIF-1β subunit within the nucleus, and regulates
transcription via hypoxia-responsive elements (HREs). Impor-
tant gene targets are involved in adaptive response to hypoxia
and include glycolytic enzymes, erythropoietin, and vascular
endothelial growth factor.
A number of lines of evidence suggest that hypoxia acts as a
homeostatic danger signal. Low oxygen levels leads to the genera-
tion of ROS, affecting both metabolism and mediators of inflam-
mation. Furthermore, it is well established that HIF-1α signaling is
closely tied to NF-kB signaling. In neutrophils, survival in hypoxic
microenvironments, such as those found in infected tissue, is
mediated by HIF-1α-dependent NF-kB activation (Walmsley et al.,
2005). In a number of cell types, including DCs, hypoxia-induced
HIF-1α prompts expression of TLR2 and TLR6 (Kuhlicke et al.,
2007). Additionally, macrophages with a conditional deficiency in
HIF-1α are compromised in their ability to clear bacteria (Cramer
et al., 2003; Peyssonnaux et al., 2005), and TLR ligands like LPS
may induce the HIF-NF-kB axis even under normoxic conditions
(Spirig et al., 2010). Indeed, hypoxia-independent HIF induction
may occur via other mechanisms, including in response to bac-
terial siderophores (Hartmann et al., 2008). Finally, hypoxia is
also known to modulate cytokine production via HIF expression,
inducing production of pro-inflammatory cytokines (Jeong et al.,
2003; Nizet and Johnson, 2009) and enhancing the production of
IFN-β in response to viral infection (Hwang et al., 2006).
Studies of DC responses to hypoxia are at times conflicting.
It is unclear if hypoxia in itself activates DCs (Jantsch et al.,
2008; Wang et al., 2010), and hypoxia may enhance (Jantsch et al.,
2008) or inhibit (Mancino et al., 2008) LPS-induced costimulatory
molecule expression. However, hypoxia does seem to augment
DC production of pro-inflammatory cytokines, particularly in
response to LPS (Jantsch et al., 2008; Mancino et al., 2008; Blengio
et al., 2013). Similar activation has been demonstrated in human
DCs associated with the inflamed joints of patients with juvenile
idiopathic arthritis (Bosco et al., 2011).
HIF-1α expression is associated with a number of inflamma-
tory and autoimmune diseases, including within the synovium
of RA patients (Hollander et al., 2001) and in the muscle from
patients with dermatomyositis and systemic sclerosis (Konttinen
et al., 2004). HIF-1α is important for the development of B cells,
with HIF-1α deficiency in chimeric mice leading to autoimmu-
nity (Kojima et al., 2002). To our knowledge, the role of HIF
signaling in DCs in the context of autoimmunity remains relatively
unexplored.
MITOCHONDRIA
As a number of excellent reviews on mitochondria-derived danger
signals have recently been published (Arnoult et al., 2011; Krysko
et al., 2011; Galluzzi et al., 2012; Rath and Haller, 2012), we can
only briefly touch on this important subject. Mitochondria are
key in both the recognition and propagation of danger signals
and we discuss them last because, as we describe in this section,
mitochondria belong to more than one category of danger signal.
As ancient symbionts, mitochondria harbor a number of mole-
cules that have bacterial origin and therefore can be considered
PAMPs. At the same time, these molecules are released from the
cell interior upon cell stress/death and therefore they act as DAMPs
and propagate the inflammatory response. Mitochondrial-derived
danger signals include mitochondrial DNA (mtDNA), which
contains CpG motifs capable of stimulating TLR9, N -formyl
peptides which mimic bacterial peptides, and ATP as described
above (Arnoult et al., 2011). The double nature of mitochon-
dria as PAMPs and DAMPs brings the models of Janeway and
Matzinger together (Seong and Matzinger, 2004), showing how
the immune system co-evolved with his “enemy within” (Zhang
et al., 2010). Moreover, as mitochondria are the cell power-house,
they are key players in programs of cell death and in control-
ling homeostatic perturbations (Desai et al., 2002; Galluzzi et al.,
2012).
Mitochondrial-derived danger signals are associated with the
inflammatory response upon tissue damage and have been impli-
cated in the inflammatory response to trauma. Severe traumatic
injury may result in SIRS, a life threatening condition in which
extensive tissue injury leads to systemic inflammation and shock
reminiscent of sepsis (Stoecklein et al., 2012). Indeed, trauma
Frontiers in Immunology | Antigen Presenting Cell Biology June 2013 | Volume 4 | Article 138 | 10
Gallo and Gallucci Dendritic cells, danger signals, and autoimmunity
patients who have sustained major tissue injury have elevated
levels of circulating mtDNA which contributes to the resultant
sterile shock (Zhang et al., 2010).
Mitochondrial-derived CpGs are also an important danger
signal in autoimmune disease. For example, injecting mtDNA
into the joints of mice induces myeloid cell-mediated arthritis,
but injection of nuclear DNA does not (Collins et al., 2004).
The authors of this study also found mtDNA in the synovial
fluid of patients with RA, but not from health controls (Collins
et al., 2004). Recently, a mitochondrial-derived protein related to
HMGB1, called mitochondrial transcription factor A, has been
found to synergize with CpG to induce the production of Type I
IFNs by pDCs (Julian et al., 2012).
Furthermore, as mitochondria are central to metabolism and
cellular energy production, they represent a key sensor of homeo-
static perturbations (Desai et al., 2002) and are known to regulate
multiple cell death programs – linking homeostatic signals to cell
death and release of danger signals (Galluzzi et al., 2012). Impor-
tantly, mitochondrial control of cell death includes the execution
of both apoptosis and regulated necrosis, the latter a form of
inflammatory cell death now known to propagate the immune
response to pathogens (Vandenabeele et al., 2010). Regulated
necrosis leads to the liberation of many danger signals, including
those we have outlined in this review.
Perturbations in homeostasis or mitochondrial function also
lead to the generation of ROS, which are an important danger sig-
nals in their own right. ROS are normal byproducts of respiration,
but may also function as signaling molecules and antimicrobial
agents under controlled conditions (Valko et al., 2007); as well as a
danger signals under pathologic conditions (Galluzzi et al., 2012).
Cells defend themselves against toxic ROS buildup using a multi-
tude of antioxidants and enzymes including superoxide dismutase
and catalase (Dröge, 2002). Superoxide dismutase converts oxygen
radicals to hydrogen peroxide and oxygen; and catalase converts
hydrogen peroxide to water and oxygen. However, when oxidative
stress overwhelms these antioxidant mechanisms the result is acti-
vation of cell death programs (Galluzzi et al., 2012). In the context
of autoimmune diseases like SLE, increased ROS may contribute
to pathogenesis via modification of self-antigens, thereby increas-
ing their auto-reactivity, and by promoting cell death resulting
in the release of DAMPs (Perl et al., 2004; Oates and Gilkeson,
2006).
In addition to being a source and sensor of danger signals,
mitochondrial dysfunction may directly influence the course of
autoimmune and autoinflammatory diseases. This seems to be
due to the participation of mitochondria in regulating the inflam-
masome and cell death. Indeed, inflammasome activation in the
context of monogenic autoinflammatory diseases has been sug-
gested to cause mitochondrial dysfunction (Escames et al., 2011).
Mitochondrial dysfunction and subsequent cell death, in response
to oxidative stress, may have a predominant role in the prop-
agation of MS (Witte et al., 2010). Mitochondria from T cells
of SLE patients also seem to be deregulated – having an ele-
vated baseline transmembrane potential, predisposing them to
necrotic cell death (Gergely et al., 2002; Perl et al., 2012) and other
metabolic disturbances (Wu et al., 2012). Continued investiga-
tion of mitochondria at the cross-roads between metabolism and
inflammation will very likely be important in our understanding
of autoimmunity.
CONCLUSION AND FUTURE PERSPECTIVES
The immune response is often described as a double-edge sword.
Too little immunity leads to uncontrolled infections, while too
much immunity results in inflammatory damage, autoinflam-
matory disease, and some forms of autoimmunity. The delicate
balance needed to keep immunity within this narrow range is
the result of complex biochemical interactions. A threshold likely
exists whereby tonic factors suppress noise in the system and other
factors amplify or regulate immunologic signals in order to have
a quick and efficient immune response (Germain, 2012). Danger
signals may be both initiators of the immune response, as well as
amplifiers of the immune response as a result of tissue injury and
cell death. Indeed, inflammatory cell death seems to be required for
proper pathogen clearance (Cho et al., 2009; Upton et al., 2010).
Another layer of complexity comes in the fact that some mole-
cules do not always act as danger signals, but rather serve other
functions (e.g., HMGB1 acts as a chemokine, HSP as a chaperone,
mitochondria as a power-house) and may even inhibit the immune
response or promote tissue repair (Castiglioni et al., 2011; Stocki
and Dickinson, 2012).
Danger signals are therefore diverse in form and func-
tion. Indeed, there are a number of conceptual frameworks in
which danger signals are characterized, all of which have been
extremely useful (Janeway, 1989; Matzinger, 1994). Here we have
outlined, to the best of our ability, both the classic, emerg-
ing and homeostatic danger signals that influence DC biology.
Although we describe some non-classic because they do not
directly derive from pathogens or dead/dying cells, they are in
fact well established. Man-made technologies (nanomaterials)
are simply a novel form of particulate matter, which has been
known for many years to induce inflammatory disease. Further-
more, the notion that homeostatic perturbations (e.g., osmotic
stress, oxidative stress) act as danger signals is supported by a
large body of literature (See “Mitochondria”). These data sug-
gest that the immune system, set to recognize tissue/cell dam-
age, can use sensors for basic physical and chemical pertur-
bations of the tissue microenvironment to detect early causes
of damage, even before the release of DAMPs. While much
is now know about DC responses to exogenous and endoge-
nous danger signals, many questions remain unresolved. Indeed,
we have discussed signals as if they act independently, but we
have little information on how signals interact with each other
to control the immune response. Future studies will determine
how the sum of these functions influences the development of
autoimmunity.
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